Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: DIPNECH is considered a rare condition and the natural history is poorly described. It is thought to give rise to pulmonary carcinoids (PCs) (>5mm) or tumourlets (≤5mm).
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Hayes A
Authors: Hayes A, Banks J, Shah H, Luong T, Navalkissoor S,
Keywords: dipnech, diffuse idiopathic neuroendocrine cell hyperplasia, tumourlet, carcinoid, neuroendocrine tumor, multiple pulmonary nodules,
Introduction: Escalated doses of SSA have been used for control of refractory symptoms and tumour growth
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Laskaratos F, Shah R, Banks J, Smith J, Jacobs B,
Keywords: above-label somatostatin analogues, neuroendocrine tumor,
Introduction: Appendiceal neuroendocrine tumours (aNETs) are usually diagnosed incidentally at appendicectomy and rarely recur. Current ENET guidelines inform their management and highlight areas of uncertainty.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author:
Authors: Alabraba E, Banks M, Malik H, Fenwick S, Cuthbertson D,
Keywords: Appendix NET,
#550 Predictors of Survival Following Y90 DOTATOC/DOTATATE Therapy
Introduction: Y90-DOTATATE and Y90-DOTATOC are established treatments for patients with advanced neuroendocrine tumours. Outcomes associated with improved survival following therapy are still unclear.
Conference: 9th Annual ENETSConcerence (2012)
Presenting Author:
Authors: Gilbert T, Mckane G, Banks M, Poston G, Vora J,
Keywords: Y90 DOTATOC/DOTATATE, survival,
Introduction: Carcinoid heart disease (CHD) affects up to 15-70% of patients with carcinoid disease. Recent ENETS guidelines recommend regular echocardiographic assessment to screen for CHD. Chromogranin A (CgA) is a peptide widely used to monitor carcinoid disease progression. Neurokinin A is a tachykinin which may be a more sensitive measure of carcinoid disease progression and prognosis. N-terminal pro Brain Naturetic Peptide is used as a screening tool for heart failure and recent results suggest utility in the diagnosis of CHD.
Conference: 7th Annual ENETSConcerence (2010)
Presenting Author:
Authors: Wong C, Burgess M, Banks M, Ardill J, Poston G,
Keywords: carcinoid disease, chromogranin A, Neurokinin A, N-Terminal Barin Naturetic Peptide, carcinoid heart disease, echocardiography,